ArriVent’s lung cancer treatment fails late-stage trial

CarrotnSticks

Ideas that power systems.

08030711042
business@carrotnsticks.com
Lagos, Nigeria

ArriVent BioPharma said ‌on Tuesday its therapy to treat patients with a type of lung cancer did not ⁠meet the main goal in a late-stage trial.

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.